Trial Enrollment Rescue Plan

{
  "$schema": "https://openpresentation.org/schema/opf/v1",
  "name": "Trial Enrollment Rescue Plan",
  "description": "Trial Enrollment Rescue Plan is a fictional OPF example for pharmaceuticals teams. It demonstrates a realistic presentation structure with catalog-backed design and content payloads.",
  "filename": "trial-enrollment-rescue-plan",
  "language": "english-us",
  "audience": [
    "candidates",
    {
      "id": "investors",
      "attentionBudgetMinutes": 30,
      "technicalFluency": "low",
      "decisionPower": "informational",
      "recommendedNarratives": [
        "focus"
      ],
      "recommendedTones": [
        "persuasive"
      ]
    }
  ],
  "purpose": {
    "id": "inform",
    "outcome": "Restore patient enrollment momentum across priority sites",
    "successCriteria": [
      "The audience can state the decision in one sentence.",
      "The owner and next checkpoint are explicit."
    ]
  },
  "tone": {
    "id": "persuasive",
    "voiceCues": [
      "Make the decision visible.",
      "Use concrete operating language."
    ],
    "avoid": [
      "Do not bury the ask.",
      "Do not over-explain obvious context."
    ]
  },
  "narrative": "focus",
  "design": {
    "theme": "bold",
    "colorScheme": {
      "id": "steel-blue",
      "primary": "#1D4ED8",
      "secondary": "#047857",
      "accent": "#B45309",
      "background": "#FFFFFF",
      "text": "#0F172A",
      "custom": {
        "signal": "#6D28D9",
        "risk": "#BE123C"
      }
    },
    "fontScheme": {
      "id": "daunpenh",
      "heading": {
        "family": "Aptos Display",
        "weight": 700
      },
      "body": {
        "family": "Aptos",
        "weight": 400
      },
      "code": {
        "family": "Consolas",
        "weight": 400
      }
    },
    "dimensions": "widescreen",
    "background": {
      "type": "solid",
      "color": "#FFFFFF",
      "opacity": 1
    },
    "titleAlignment": "left",
    "contentAlignment": "center",
    "contentBox": true,
    "contentDirection": "horizontal",
    "chartPrimary": "right",
    "imageFill": "crop",
    "listBullet": "character",
    "logo": {
      "default": "asset:brand-logo",
      "light": "asset:brand-logo-light",
      "icon": "asset:brand-icon",
      "wordmark": "asset:brand-logo"
    },
    "watermark": {
      "src": "asset:watermark",
      "opacity": 0.06
    },
    "header": {
      "left": {
        "section": true
      },
      "right": {
        "image": "asset:brand-icon"
      }
    },
    "footer": {
      "left": {
        "organization": true
      },
      "center": {
        "text": "Internal planning draft"
      },
      "right": {
        "slideNumber": true
      }
    },
    "slideImage": {
      "src": "asset:cover-bg",
      "position": "bottom"
    }
  },
  "slides": [
    {
      "id": "s1",
      "section": "Opening",
      "layout": "title-subtitle",
      "tag": "Pharmaceuticals",
      "title": "Trial Enrollment Rescue Plan",
      "subtitle": "Novara Therapeutics Pharmaceuticals",
      "notes": "Open by naming the decision: Restore patient enrollment momentum across priority sites."
    },
    {
      "id": "s2",
      "section": "Context",
      "layout": "text-1x",
      "title": "Why This Matters",
      "text": [
        "Novara Therapeutics should focus the next cycle on ",
        {
          "text": "restore patient enrollment momentum across priority sites",
          "bold": true,
          "color": "#1D4ED8"
        },
        " while making the operating tradeoffs clear to pharmaceuticals stakeholders."
      ]
    },
    {
      "id": "s3",
      "section": "Evidence",
      "layout": "chart-1x",
      "title": "Signal Trend",
      "type": "chart",
      "chart": {
        "type": "100pct-stacked-column-3x",
        "data": {
          "columns": [
            "Quarter",
            "Current",
            "Baseline"
          ],
          "rows": [
            [
              "Q1",
              24,
              21
            ],
            [
              "Q2",
              28,
              23
            ],
            [
              "Q3",
              31,
              25
            ],
            [
              "Q4",
              35,
              27
            ]
          ]
        }
      }
    },
    {
      "id": "s4",
      "section": "Options",
      "layout": "table-1x",
      "title": "Decision Options",
      "table": {
        "columns": [
          "Workstream",
          "Owner",
          "Status",
          "Decision"
        ],
        "rows": [
          [
            "Pharmaceuticals",
            "Program lead",
            "On track",
            "Continue"
          ],
          [
            "Data and reporting",
            "Analytics",
            "Watch",
            "Tighten metric definitions"
          ],
          [
            "Field adoption",
            "Operations",
            "At risk",
            "Add weekly office hours"
          ]
        ]
      }
    },
    {
      "id": "s5",
      "section": "Plan",
      "layout": "text-2x",
      "title": "Execution Timeline",
      "type": "timeline",
      "timeline": {
        "name": "Pharmaceuticals execution path",
        "description": "Major milestones for Novara Therapeutics.",
        "events": [
          {
            "when": "May",
            "what": "Baseline",
            "description": "Confirm current state, owners, and constraints."
          },
          {
            "when": "Jun",
            "what": "Pilot",
            "description": "Run a narrow pilot with visible success criteria."
          },
          {
            "when": "Jul",
            "what": "Scale",
            "description": "Expand the approach after risk review."
          },
          {
            "when": "Aug",
            "what": "Embed",
            "description": "Move reporting and routines into steady-state operations."
          }
        ]
      }
    },
    {
      "id": "s6",
      "section": "Close",
      "layout": "list-3x",
      "title": "The Ask",
      "bullets": [
        {
          "text": "Approve the next milestone for restore patient enrollment momentum across priority sites.",
          "level": 0
        },
        {
          "text": "Assign an executive sponsor and one accountable owner.",
          "level": 0
        },
        {
          "text": "Review progress in the next operating meeting.",
          "level": 0
        }
      ]
    }
  ],
  "organization": {
    "id": "novara-therapeutics",
    "name": "Novara Therapeutics",
    "legalName": "Novara Therapeutics, Inc.",
    "logo": "asset:brand-logo",
    "domain": "novara-therapeutics.example",
    "email": "hello@novara-therapeutics.example",
    "phone": "+15551000012",
    "tagline": "Restore patient enrollment momentum across priority sites",
    "role": "primary",
    "socials": {
      "github": "@novara-therapeutics",
      "mastodon": "https://mastodon.example/novara-therapeutics"
    }
  },
  "speaker": [
    {
      "id": "maya",
      "name": "Maya Chen",
      "title": "Program Sponsor",
      "photo": "asset:supporting-photo",
      "email": "maya@novara-therapeutics.example",
      "organizationId": "novara-therapeutics",
      "socials": {
        "github": "@maya-chen"
      }
    },
    {
      "id": "jon",
      "name": "Jon Alvarez",
      "title": "Operating Lead",
      "organizationId": "novara-therapeutics",
      "socials": {
        "mastodon": "@jon-alvarez"
      }
    }
  ],
  "author": [
    "OPF Example Generator",
    "Open Presentation"
  ],
  "takeaway": [
    "Restore patient enrollment momentum across priority sites",
    "The next decision and owner should be visible on the final slide."
  ],
  "duration": 20,
  "tags": [
    "industries",
    "pharmaceuticals",
    "inform",
    "persuasive",
    "medium"
  ],
  "assets": {
    "brand-logo": {
      "src": "./assets/novara-therapeutics-logo.svg",
      "alt": "Novara Therapeutics logo",
      "mediaType": "image/svg+xml"
    },
    "brand-logo-light": {
      "src": "./assets/novara-therapeutics-logo-light.svg",
      "alt": "Novara Therapeutics light logo",
      "mediaType": "image/svg+xml"
    },
    "brand-icon": {
      "src": "./assets/novara-therapeutics-icon.svg",
      "alt": "Novara Therapeutics icon",
      "mediaType": "image/svg+xml"
    },
    "cover-bg": {
      "src": "./assets/novara-therapeutics-cover-3.jpg",
      "alt": "Pharmaceuticals background image",
      "mediaType": "image/jpeg"
    },
    "supporting-photo": {
      "src": "./assets/novara-therapeutics-field-photo.jpg",
      "alt": "Pharmaceuticals field context",
      "mediaType": "image/jpeg"
    },
    "demo-video": {
      "src": "./media/novara-therapeutics-demo.mp4",
      "title": "Pharmaceuticals walkthrough",
      "mediaType": "video/mp4"
    },
    "metric-data": {
      "src": "./data/trial-enrollment-rescue-plan.csv",
      "format": "csv",
      "title": "Trial Enrollment Rescue Plan data"
    },
    "watermark": {
      "src": "./assets/novara-therapeutics-watermark.png",
      "alt": "Novara Therapeutics watermark",
      "mediaType": "image/png"
    }
  },
  "extensions": {
    "example": {
      "folder": "industries",
      "density": "medium",
      "scenario": "trial-enrollment-rescue-plan",
      "generatedBy": "scripts/generate-example-suite.mjs"
    }
  }
}